Meeting
2014 ASCO Quality Care Symposium
An assessment of neoadjuvant therapy for breast cancer and treatment wait times at the BC Cancer Agency Vancouver.
Authors
Rachel Adilman
BC Cancer Agency, Vancouver, BC, Canada
Rachel Adilman, Robyn Leonard, Zia Poonja, Christine E. Simmons
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
General Poster Session B: Cost, Value, and Policy in Quality and Practice of Quality
Track
Practice of Quality,Cost, Value, and Policy in Quality
Sub Track
Learning from Projects Done in a Health System
Citation
J Clin Oncol 32, 2014 (suppl 30; abstr 140)
DOI
10.1200/jco.2014.32.30_suppl.140
Abstract #
140
Poster Bd #
F8
Abstract Disclosures
Similar Posters
Poster
2020 ASCO Virtual Scientific Program
Comprehensive profiling of androgen receptor-positive (AR+) triple-negative breast cancer (TNBC) patients (pts) treated with standard neoadjuvant therapy (NAT) +/- enzalutamide.
First Author: Bora Lim
Poster
2018 ASCO Quality Care Symposium
Institutional adherence to National Comprehensive Cancer Network (NCCN) guidelines in neoadjuvant treatment of breast cancer and its correlation to outcomes.
First Author: Raju Kumar Vaddepally
Poster
2018 ASCO Annual Meeting
Dynamic genomic instability modulation by neoadjuvant therapy in early breast cancer (GEICAM/2006-03_2006-14).
First Author: Emilio Alba
Poster
2014 ASCO Annual Meeting
A pilot study of dose-dense (biweekly) carboplatin plus paclitaxel with or without trastuzumab as neoadjuvant treatment for breast cancer.
First Author: Teng Zhu